A Bayesian tool for optimizing sample size in phase I dose-finding trials for head and neck cancer by Sivakamavalli Jeyachandran

Subjects: Get full text

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors by Nathaniel J. Myall, MD, Jennifer G. Whisenant, PhD, Joel W. Neal, MD, PhD, Wade T. Iams, MD, Karen L. Reckamp, MD, Sally York, MD, PhD, Lynne D. Berry, PhD, Yu Shyr, PhD, Leora Horn, MD, Heather A. Wakelee, MD, Sukhmani K. Padda, MD

Subjects: Get full text

Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma by D. König, B. Kasenda, M. Sandholzer, A. Chirindel, A. Zingg, R. Ritschard, H. Thut, K. Glatz, E.A. Kappos, D. Schaefer, C. Kettelhack, J. Passweg, K. Baur, A. Holbro, A. Buser, D. Lardinois, L.T. Jeker, N. Khanna, F. Stenner, M.S. Matter, N. Rodrigues Mantuano, M. Binder, A. Zippelius, H. Läubli

Subjects: Get full text

A phase I study using bortezomib (Velcade), cladribine, and rituximab in treating patients over 50 years old with mantle cell lymphoma by Jeffrey J. Pu, Jeffrey J. Pu, Kristin N. Berger, Chunlei Zheng, Chunlei Zheng, Nhan Do, Nhan Do, David F. Claxton, W. Christopher Ehmann, Joseph J. Drabick, Haiquan Li, Thomas P. Loughran, Elliot M. Epner

Subjects: Get full text